Skip to main content
. 2011 Mar;178(3):1153–1166. doi: 10.1016/j.ajpath.2010.11.052

Figure 3.

Figure 3

Treatment with BCP changes colonic protein levels and mRNA expression of inflammatory mediators. At the end of 7 days, colon tissue was collected and processed for cytokine levels and mRNA expression. A–E: Enzyme-linked immunosorbent assay. Preventive treatment with BCP (50 mg/kg, p.o.) reduced colonic levels of tumor necrosis factor-α (TNF-α) (A), IL-1β (B), keratinocyte-derived chemokine (CXCL1/KC) (C), and interferon–γ (IFN-γ) (D) and restored levels of IL-4 (E). F–J: Real-time PCR. The same scheme of treatment with BCP also impaired the increase colonic mRNA expression of TNF-α (F), IL-1β (G), CXCL1/KC (H), and IFN-γ (I). In addition, BCP treatment increased colonic forkhead box P3 (Foxp3) mRNA expression (J) as assessed by real-time PCR. The real-time PCR assay was performed in duplicate and GAPDH mRNA was used to normalize the relative amount of mRNA. Data are reported as means ± SEM (n = 5 to 7 mice per group). *P < 0.05 versus the DSS-treated group; **P < 0.05 versus the control group.